JP2009511450A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009511450A5 JP2009511450A5 JP2008534023A JP2008534023A JP2009511450A5 JP 2009511450 A5 JP2009511450 A5 JP 2009511450A5 JP 2008534023 A JP2008534023 A JP 2008534023A JP 2008534023 A JP2008534023 A JP 2008534023A JP 2009511450 A5 JP2009511450 A5 JP 2009511450A5
- Authority
- JP
- Japan
- Prior art keywords
- leukemia
- methyl
- formula
- pharmaceutical combination
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72459405P | 2005-10-07 | 2005-10-07 | |
| PCT/EP2006/067117 WO2007042465A2 (en) | 2005-10-07 | 2006-10-05 | Combinati0n of nilotinib with farnesyl transferase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009511450A JP2009511450A (ja) | 2009-03-19 |
| JP2009511450A5 true JP2009511450A5 (https=) | 2009-09-17 |
Family
ID=37943163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008534023A Pending JP2009511450A (ja) | 2005-10-07 | 2006-10-05 | ニロチニブとファルネシルトランスフェラーゼ阻害剤の組合せ |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20080255171A1 (https=) |
| JP (1) | JP2009511450A (https=) |
| WO (1) | WO2007042465A2 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2644143C (en) * | 2006-04-05 | 2013-10-01 | Novartis Ag | Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer |
| WO2009151683A2 (en) | 2008-03-12 | 2009-12-17 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
| NZ593090A (en) | 2008-11-13 | 2013-06-28 | Link Medicine Corp | Azaquinolinone derivatives and uses thereof |
| US20110294794A1 (en) * | 2008-11-13 | 2011-12-01 | Link Medicine Corporation | Treatment of proteinopathies using a farnesyl transferase inhibitor |
| US20170368038A1 (en) * | 2014-12-18 | 2017-12-28 | Novartis Ag | Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1322334A2 (en) * | 2000-10-05 | 2003-07-02 | George Q. Daley | Methods of inducing cancer cell death and tumor regression |
| US20020077301A1 (en) * | 2000-10-05 | 2002-06-20 | Whitehead Institute For Biomedical Research | Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors |
| CN1617755A (zh) * | 2001-11-30 | 2005-05-18 | 先灵公司 | 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用 |
| GB0215676D0 (en) * | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
-
2006
- 2006-10-05 US US12/089,317 patent/US20080255171A1/en not_active Abandoned
- 2006-10-05 WO PCT/EP2006/067117 patent/WO2007042465A2/en not_active Ceased
- 2006-10-05 JP JP2008534023A patent/JP2009511450A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009511450A5 (https=) | ||
| JP2013531028A5 (https=) | ||
| JP2009532438A5 (https=) | ||
| JP2015508749A5 (https=) | ||
| JP2006523216A5 (https=) | ||
| JP2017528507A5 (https=) | ||
| JP2005502643A5 (https=) | ||
| HRP20120144T1 (en) | Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity | |
| JP2013523733A5 (https=) | ||
| JP2017504611A5 (https=) | ||
| JP2017505293A5 (https=) | ||
| JP2010515715A5 (https=) | ||
| JP2014502641A5 (https=) | ||
| JP2024540183A5 (https=) | ||
| JP2020512337A5 (https=) | ||
| CN111902417A (zh) | 一种二芳基巨环化合物、药物组合物以及其用途 | |
| RU2008143703A (ru) | ПРИМЕНЕНИЕ ИНГИБИТОРОВ c-Src В КОМБИНАЦИИ С ПИРИМИДИЛАМИНОБЕНЗАМИДОМ ДЛЯ ЛЕЧЕНИЯ ЛЕЙКОЗА | |
| JP2009511568A5 (https=) | ||
| NZ590839A (en) | Treatment of pulmonary arterial hypertension | |
| JPWO2020175629A5 (https=) | ||
| JP2008536853A5 (https=) | ||
| JP2008519049A5 (https=) | ||
| JP2020500868A5 (https=) | ||
| JP2019501134A5 (https=) | ||
| JP2013544794A5 (https=) |